Drugs / PVRV-NG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01339312 | Apr 2011 → Mar 2012 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVRV-NG | “As an evolution of its currently licensed rabies vaccine Verorab(®), Sanofi Pasteur has developed a next-generation, serum-free, highly purified Vero rabies vaccine (PVRV-NG).” PMID 24148575 ↗ Oct 2013 |
| Modality | Vaccine | “a next-generation, serum-free, highly purified Vero rabies vaccine (PVRV-NG)” PMID 24148575 ↗ Oct 2013 |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01339312 ↗ |